Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
Coronavirus information
Coronavirus information
The Zero Canada Project provides resources to help you manage your health, your finances and your family life as Canada reopens.
Visit the hub

A hospital worker wearing a face shield and mask is seen at a COVID-19 assessment centre for staff at Lions Gate Hospital, in North Vancouver, on March 19, 2020.

DARRYL DYCK/The Canadian Press

In the race to find a treatment that works against COVID-19, scientists have been testing drugs that impede viruses in human cells as well as those that can calm the immune system so that the body’s response to infection is less severe.

Now, a Canadian company is trying a different strategy. Using a specially engineered nasal spray, it hopes to make subjects’ airways a hostile environment for the virus so that an infection can’t get started.

The company, SaNOtize Research and Development Corp. of Vancouver, announced on Wednesday that it has received approval from Health Canada to begin a clinical trial of its method, which hinges on the delivery of nitric oxide gas to the upper-respiratory tract.

Story continues below advertisement

Clinical trials to begin this week as Oxford researchers race to develop COVID-19 vaccine

‘You find a way.’ How one B.C. elementary school is teaching children of essential workers

Ottawa creates new benefit to help students, recent graduates without summer jobs due to COVID-19 pandemic

The chemical, which has antiviral properties, is released from a liquid solution developed by the company and which can be used in different ways, including as a nasal spray. Laboratory tests conducted last week at the Institute for Antiviral Research at Utah State University show the solution is effective against the virus that causes COVID-19.

If the same approach works in people, it opens the door to a preventative treatment for those who are at high risk of exposure to COVID-19, including front-line health care workers. More broadly, it could help protect anyone in a public setting once physical-distancing measures are lifted.

“We are trying to rapidly move this forward and provide a prevention that would help us resume social and economic activity while we wait for a vaccine to be developed,” said Chris Miller, the company’s chief science officer, who has been studying nitric oxide’s potential as an antimicrobial agent since the 1990s.

That hope is balanced by the reality that, so far, no drug has been shown to be safe and effective for treating COVID-19 according to treatment guidelines released on Tuesday by the U.S. National Institutes of Health.

Nitric oxide – not to be confused with nitrous oxide or laughing gas – is a simple molecule consisting of one nitrogen and one oxygen atom. Because of its small size and biochemical properties, it easily penetrates cells and plays multiple roles in the human body.

One of those roles is to serve as a short-range weapon against foreign invaders when it is produced by immune cells. Nitric oxide has also been shown to deter viruses, including influenza and, in one 2009 study, the SARS coronavirus.

Dr. Miller said that the tiny but reactive molecule is thought to alter the coronavirus’s protruding crown of proteins that it uses to latch onto cells. Inside cells, it can also interfere with the virus’s ability to replicate.

Story continues below advertisement

In a hospital environment, the gas can be delivered safely to a patient’s respiratory tract from a pressured cylinder. This method is now being investigated at a number of sites as a potential treatment for those with COVID-19 infections. In one randomized trial, led by Massachusetts General Hospital in Boston, nitric oxide is also being administered to hospital workers for 15 minutes before and after their shifts to test whether it reduces their rate of infection.

“We’re hoping that will prevent caregivers from developing the disease,” Robert Kacmarek, the hospital’s director of respiratory care, said in an interview with Boston’s WBUR radio.

Where SaNOtize differs is in the use of a solution that releases nitric oxide at the required dose and at the point where it’s needed without hospital equipment or expert supervision.

Dr. Miller said the clinical trial, which could begin recruiting subjects as early as next week, would test a combined use of the solution through daily gargling, a thorough nasal rinse and repeated application as a nasal spray.

“It’s much like hand sanitizer for the nose,” he said.

The trial will determine if a group of subjects in a high infection-risk environment are less likely than a control group to develop symptoms of COVID-19. Those in the control group who become infected will then be offered the solution as a form of early treatment in a separate arm of the trial.

Story continues below advertisement

Before the COVID-19 outbreak, Dr. Miller said he and his colleagues were testing the solution as a treatment for chronic sinusitis. This prior work allowed them to pivot quickly when the pandemic hit.

Outside of humans, the company has also been testing the solution for effectiveness at preventing shipping fever, a cattle ailment caused by a combination of bacterial and viral infections.

John Church, a researcher at Thompson Rivers University in Kamloops, B.C., who is collaborating on the cattle tests, said the solution performed as well as antibiotics at reducing infections.

“I was really quite surprised a how long lasting the effect was,” he said.

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Follow related topics

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies